TABLE 2

Laboratory findings in patients with COVID-19 pneumonia

CharacteristicsTotalDeceasedSurvivorsp-value
Patients17921158
White blood cells ×109cells·L−15.3 (3.9–7.8)8.9 (4.8–13.1)5.1 (3.8–7.3)0.003
Neutrophils ×109cells·L−14.0 (2.7–6.6)7.7 (3.0–11.5)3.9 (2.6–6.1)0.007
Lymphocytes ×109cells·L−10.8 (0.6–1.1)0.7 (0.5–0.8)0.8 (0.6–1.1)0.046
T-cell subsets
 CD3+CD4+ cells·μL−1114.3 (62.9–195.3)68.0 (55.1–148.8)128.3 (73.5–201.7)0.066
 CD3+CD8+ cells·μL−175.5 (45.5–125.0)47.9 (25.4–73.8)104.5 (58.5–142.7)0.001
C-reactive protein mg·L−139.8 (20.6–97.8)86.4 (37.9–105.5)36.0 (19.3–91.0)0.012
Procalcitonin ng·mL−10.1 (0.0–0.2)0.1 (0.1–0.5)0.1 (0.0–0.2)0.013
Cardiac troponin I ng·mL−10.0 (0.0–0.1)0.1 (0.0–0.8)0.0 (0.0–0.0)<0.001
Myoglobin ng·mL−136.9 (18.4–124.0)162.0 (48.5–342.8)32.3 (15.5–60.3)<0.001
Brain natriuretic peptide pg·mL−1645.0 (110.0–1504.0)970.0 (620.5–3531.0)390.0 (58.0–1118.5)0.004
Albumin g·L−133.2 (30.7–36.4)33.2 (31.2–35.6)33.0 (30.6–38.1)0.764
Total bilirubin μmol·L−18.9 (6.6–12.5)9.6 (8.3–16.3)8.7 (6.5–12.3)0.146
Direct bilirubin μmol·L−12.5 (1.8–3.9)3.1 (2.3–6.1)2.4 (1.8–3.8)0.101
Alanine aminotransferase U·L−122.0 (15.0–40.0)27.0 (20.0–37.0)22.0 (14.0–40.5)0.233
Aspartate aminotransferase U·L−130.0 (19.0–43.0)40.0 (27.0–61.5)27.5 (19.0–42.0)0.010
γ-Glutamyltranspeptidase U·L−129.0 (17.0–52.5)23.0 (16.5–42.0)29.0 (17.0–54.5)0.518
Creatinine μmol·L−166.5 (55.8–82.0)95.0 (63.0–112.0)65.0 (55.0–80.0)0.001
D-dimer mg·L−10.5 (0.3–1.7)1.1 (0.4–10.5)0.5 (0.3–1.2)0.011
Prothrombin time s13.7 (12.4–15.4)13.9 (12.3–16.3)13.7 (12.4–15.2)0.758
Activated partial thromboplastin time s35.6 (31.0–39.4)37.8 (30.8–41.5)35.3 (30.9–39.1)0.383
PaO2 mmHg72.0 (57.0– 88.0)56.0 (49.0 –71.0)74.5 (59.0–92.0)0.001
PaCO2 mmHg37.0 (33.0– 41.0)34.0 (29.0–41.0)37.0 (34.0–41.0)0.068
PaO2:FIO2 mmHg249.6±106.1185.5±64.8261.5±108.20.002

Data are presented as n, median (interquartile range) or mean±sd, unless otherwise stated. PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; FIO2: inspiratory oxygen fraction.